SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sequent Scientific gains on securing approval for investing up to Rs 150 crore in Shasun Pharma

25 Apr 2014 Evaluate

Sequent Scientific is currently trading at Rs. 256.00, up by 0.95 points or 0.37 % from its previous closing of Rs. 255.05 on the BSE.

The scrip opened at Rs. 259.00 and has touched a high and low of Rs. 262.95 and Rs. 249.50 respectively. So far 7692 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 274.00 on 22-Apr-2014 and a 52 week low of Rs. 81.30 on 31-Jul-2013.

Last one week high and low of the scrip stood at Rs. 274.00 and Rs. 229.00 respectively. The current market cap of the company is Rs. 699.78 crore.

The promoters holding in the company stood at 65.35 % while Institutions and Non-Institutions held 0.15 % and 34.50 % respectively. 

Sequent Scientific has received board's approval for investment of up to Rs 150 crore in the equity capital/ convertible warrants of Shasun Pharmaceuticals. The investment is subject to statutory and other approvals, as may be applicable, including approval of shareholders under section 186 of the Companies Act, 2013.

The board also approved to increase the authorized capital of the company from Rs 32 crore to Rs 40 crore by addition of 8,000,000 equity shares of Rs 10 each and related amendments to Memorandum of Association and Articles of Association of the company.

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

Viyash Scientific Share Price

223.00 -2.30 (-1.02%)
12-May-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1870.90
Dr. Reddys Lab 1273.50
Cipla 1301.00
Zydus Lifesciences 945.80
Lupin 2242.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×